Screener
Eligibility screening
GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab
13 US sites in CA, CO, CT, FL +8
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.
Screener
GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab
13 US sites in CA, CO, CT, FL +8
Before we begin
Your answer affects how the questions are phrased.